Compare Fox Corp Class A (FOXA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

FOXA trades at $64.03, up 3.63% on strong Q4 2026 earnings beats driven by World Cup advertising and Tubi streaming growth. The stock shows bullish technical momentum with a consensus price target of $65.33, supported by a 50% buy rating from analysts. Revenue grew to $16.30B in 2025, with net income margin expanding to 13.88%, though 2026 projections indicate moderation.

Outlook remains positive with digital ad momentum and strategic initiatives, but risks include sports cost pressures and cyclical advertising dependence. The current valuation at a P/E of 16.52 appears reasonable relative to earnings growth, offering potential upside if execution continues.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.